Form 4: REGENXBIO Executive Sells Shares Under 10b5-1 Plan

REGENXBIO Inc. Chief Medical Officer Steve Pakola reported transactions involving the sale of common stock and the exercise of stock options, executed under a pre-arranged trading plan.

Summary

• Steve Pakola, Chief Medical Officer at REGENXBIO Inc., engaged in several transactions on June 29, 2026, and July 1, 2026.
• On June 29, 2026, Pakola sold 19,608 shares of common stock at a weighted average price of $11.04 per share, pursuant to a Rule 10b5-1 trading plan.
• Following this sale, Pakola beneficially owned 213,009 shares of common stock.
• On July 1, 2026, Pakola exercised stock options to acquire 36,725 shares at an exercise price of $7.86 per share.
• Concurrently on July 1, 2026, Pakola sold these 36,725 shares at a price of $12.86 per share.
• After these transactions, Pakola's beneficial ownership of common stock remained at 213,009 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider sales can be a negative signal, the use of a Rule 10b5-1 plan mitigates concerns about opportunistic selling, and the option exercise shows a profitable transaction for the executive.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-impacting sales.
• The exercise of stock options and subsequent sale at a higher price ($12.86 vs $7.86 exercise price) demonstrates a profitable transaction for the executive.

Negatives

• The reporting person sold a significant number of shares (19,608 shares on June 29 and 36,725 shares on July 1), which could be interpreted negatively by the market if not for the 10b5-1 plan context.
• The weighted average sale price on June 29 ($11.04) was lower than the sale price on July 1 ($12.86), suggesting a potential dip in stock value between the transactions.

Risks

• The sale of shares by a key executive, even under a 10b5-1 plan, can sometimes be perceived as a lack of confidence in future stock performance.
• The weighted average sale price on June 29, 2026, was $11.04, with transactions ranging from $11.00 to $11.18, indicating some price volatility around that period.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions by an insider.

Management Comments

• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• The previously granted option, representing a right to purchase a total of 103,698 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 2, 2026, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by REGENXBIO's Chief Medical Officer is a common practice to manage potential conflicts of interest and insider trading concerns, allowing executives to pre-plan stock sales during specific periods.

Stakeholder Impact

• Shareholders: May observe insider selling, but the Rule 10b5-1 plan context suggests it's pre-planned and not necessarily a reflection of negative future outlook.
• Employees: The vesting schedule for stock options serves as an incentive for continued employment and performance.
• Management: Demonstrates adherence to disclosure requirements and established trading plans.

Next Steps

• Continuous vesting of stock options over the next 36 months, contingent on continued service to the Issuer.
• Potential future transactions by Steve Pakola, subject to the terms of his Rule 10b5-1 plan and other applicable regulations.

Key Dates

Keywords

REGENXBIO, RGNX, Form 4, Steve Pakola, Stock Options, Insider Trading, Rule 10b5-1, Beneficial Ownership, Securities Exchange Act